Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

15 января 2015 г. обновлено: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma

To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

335

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Болгария
      • Lovech, Болгария, 5500
        • Novartis Investigative Site
      • Pleven, Болгария, 5800
        • Novartis Investigative Site
      • Plovdiv, Болгария, 4002
        • Novartis Investigative Site
      • Ruse, Болгария, 7002
        • Novartis Investigative Site
      • Sofia, Болгария, 1431
        • Novartis Investigative Site
      • Sofia, Болгария, 1233
        • Novartis Investigative Site
      • Sofia, Болгария, 1606
        • Novartis Investigative Site
      • Sofia, Болгария, 1612
        • Novartis Investigative Site
      • Sofia, Болгария, 1000
        • Novartis Investigative Site
      • Sofia, Болгария, 1234
        • Novartis Investigative Site
      • Sofia, Болгария, 1463
        • Novartis Investigative Site
      • Varna, Болгария, 9000
        • Novartis Investigative Site
      • Varna, Болгария, 9020
        • Novartis Investigative Site
      • Veliko Tarnovo, Болгария, 5000
        • Novartis Investigative Site
  • Германия
      • Bad Woerishofen, Германия, 86825
        • Novartis Investigative Site
      • Bonn, Германия, 53123
        • Novartis Investigative Site
      • Dortmund, Германия, 44263
        • Novartis Investigative Site
      • Dresden, Германия, 01307
        • Novartis Investigative Site
      • Frankfurt, Германия, 60596
        • Novartis Investigative Site
      • Lübeck, Германия, 23552
        • Novartis Investigative Site
      • Mainz, Германия, 55131
        • Novartis Investigative Site
      • Muenchen, Германия, 81677
        • Novartis Investigative Site
      • Wiesbaden, Германия, 65187
        • Novartis Investigative Site
      • Wiesloch, Германия, 69168
        • Novartis Investigative Site
  • Канада
    • Ontario
      • Brampton, Ontario, Канада, L6T 0G1
        • Novartis Investigative Site
      • Downsview, Ontario, Канада, M3N 2Z9
        • Novartis Investigative Site
      • Etobicoke, Ontario, Канада, M9V 4B4
        • Novartis Investigative Site
      • Grimsby, Ontario, Канада, L3M 1P3
        • Novartis Investigative Site
      • Hamilton, Ontario, Канада, L8N 3Z5
        • Novartis Investigative Site
      • Newmarket, Ontario, Канада, L3Y 5G8
        • Novartis Investigative Site
      • Toronto, Ontario, Канада, M5T 3A9
        • Novartis Investigative Site
      • Woodstock, Ontario, Канада, N4S 5P5
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Канада, H4J 1C5
        • Novartis Investigative Site
      • Pointe-Claire, Quebec, Канада, H9R 4S3
        • Novartis Investigative Site
      • St-Romuald, Quebec, Канада, G6W 5M6
        • Novartis Investigative Site
      • Ste-Foy, Quebec, Канада, G1W 4R4
        • Novartis Investigative Site
  • Корея, Республика
      • Seoul, Корея, Республика, 120-752
        • Novartis Investigative Site
      • Seoul, Корея, Республика, 158-710
        • Novartis Investigative Site
      • Seoul, Корея, Республика, 152-703
        • Novartis Investigative Site
      • Seoul, Корея, Республика, 100-032
        • Novartis Investigative Site
    • Chungbuk
      • Cheongju, Chungbuk, Корея, Республика, 361 711
        • Novartis Investigative Site
    • Gangwon-Do
      • Wonju, Gangwon-Do, Корея, Республика, 220-701
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Корея, Республика, 110 744
        • Novartis Investigative Site
  • Нидерланды
      • Rotterdam, Нидерланды, 3045 PM
        • Novartis Investigative Site
      • Sittard-Geleen, Нидерланды, 6162 BG
        • Novartis Investigative Site
  • Польша
      • Bialystok, Польша, 15-461
        • Novartis Investigative Site
      • Bienkowka, Польша, 34-212
        • Novartis Investigative Site
      • Bydgoszcz, Польша, 85-046
        • Novartis Investigative Site
      • Gdansk, Польша, 80-958
        • Novartis Investigative Site
      • Krakow, Польша, 31-023
        • Novartis Investigative Site
      • Lodz, Польша, 90-302
        • Novartis Investigative Site
      • Lodz, Польша, 90-242
        • Novartis Investigative Site
      • Lublin, Польша, 20-637
        • Novartis Investigative Site
      • Lublin, Польша, 20-044
        • Novartis Investigative Site
      • Torun, Польша, 87-100
        • Novartis Investigative Site
      • Wroclaw, Польша, 50-088
        • Novartis Investigative Site
      • Znin, Польша, 88-400
        • Novartis Investigative Site
  • Словакия
      • Dunajska Streda, Словакия, 929 01
        • Novartis Investigative Site
      • Komarno, Словакия, 945 01
        • Novartis Investigative Site
      • Kosice, Словакия, 040 01
        • Novartis Investigative Site
      • Liptovsky Hradok, Словакия, 033 01
        • Novartis Investigative Site
      • Liptovsky Mikulas, Словакия, 031 23
        • Novartis Investigative Site
      • Nove Zamky, Словакия, 940 01
        • Novartis Investigative Site
      • Rimavska Sobota, Словакия, 979 01
        • Novartis Investigative Site
      • Spisská Nová Ves, Словакия, 052 01
        • Novartis Investigative Site
      • Topolcany, Словакия, 955 01
        • Novartis Investigative Site
      • Vysne Hagy, Словакия, 5984
        • Novartis Investigative Site
      • Zvolen, Словакия, 960 01
        • Novartis Investigative Site
    • Slovak Republic
      • Banska Bystrica, Slovak Republic, Словакия, 975 17
        • Novartis Investigative Site
      • Bardejov, Slovak Republic, Словакия, 085 01
        • Novartis Investigative Site
    • Slovak republic
      • Levice, Slovak republic, Словакия, 934 01
        • Novartis Investigative Site
  • Япония
      • Fukuoka, Япония, 811-1394
        • Novartis Investigative Site
      • Gifu, Япония, 502-8558
        • Novartis Investigative Site
    • Fukuoka
      • Yanagawa, Fukuoka, Япония, 832-0059
        • Novartis Investigative Site
    • Hokkaido
      • Obihiro, Hokkaido, Япония, 080-0805
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Япония, 060-0061
        • Novartis Investigative Site
    • Hyogo
      • Himeji-city, Hyogo, Япония, 672-8064
        • Novartis Investigative Site
    • Hyogo-Ken
      • Ako-shi, Hyogo-Ken, Япония, 678-0241
        • Novartis Investigative Site
    • Ibaraki
      • Naka-gun, Ibaraki, Япония, 319-1113
        • Novartis Investigative Site
    • Kagawa
      • Sakaide, Kagawa, Япония, 762-0031
        • Novartis Investigative Site
    • Kyoto-Fu
      • Kyoto-shi, Kyoto-Fu, Япония, 615-8256
        • Novartis Investigative Site
    • Mie
      • Tsu, Mie, Япония, 514-1101
        • Novartis Investigative Site
    • Oita
      • Beppu, Oita, Япония, 874-0937
        • Novartis Investigative Site
    • Oita-Ken
      • Oita-shi, Oita-Ken, Япония, 870-0021
        • Novartis Investigative Site
    • Osaka
      • Kishiwada, Osaka, Япония, 596-8501
        • Novartis Investigative Site
    • Tokyo
      • Chuo-ku, Tokyo, Япония, 103-0027
        • Novartis Investigative Site
      • Cyuo-ku, Tokyo, Япония, 104-8560
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Япония, 173-8610
        • Novartis Investigative Site
      • Kiyose-city, Tokyo, Япония, 204-8585
        • Novartis Investigative Site
      • Setagaya-ku, Tokyo, Япония, 158-0097
        • Novartis Investigative Site
    • Tokyo-To
      • Machida-shi, Tokyo-To, Япония, 194-0023
        • Novartis Investigative Site
      • Ota-ku, Tokyo-To, Япония, 144-0035
        • Novartis Investigative Site
    • Yamagata
      • Yonezawa, Yamagata, Япония, 992-0045
        • Novartis Investigative Site

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who additionally meet the following criteria:
  • Patients who are receiving ICS treatment in a stable regimen for ≥ 4 weeks
  • Patients with a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% of predicted normal value
  • Patients who demonstrate an increase of >= 12% and 200 mL in FEV1
  • ACQ-5 score ≥ 1.5

Exclusion Criteria:

  • Patients who are current smokers or have a smoking history of greater than 10 pack years (defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked).
  • Patients with chronic lung disease, including COPD, pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.
  • Patients with any chronic conditions affecting the respiratory tract (e.g., chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.

Other protocol-defined inclusion/exclusion criteria may apply

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: indacaterol acetate 75 µg

indacaterol acetate 75 µg od delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od
Лекарство: indacaterol
indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
Лекарство: mometasone furoate
via Twisthaler inhaler
Экспериментальный: indacaterol acetate 150 µg

indacaterol acetate 150 µg od delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od
Лекарство: indacaterol
indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
Лекарство: mometasone furoate
via Twisthaler inhaler
Плацебо Компаратор: placebo

placebo delivered via Concept 1 inhaler

Background therapy: mometasone furoate 200 mcg od
Лекарство: mometasone furoate
via Twisthaler inhaler
Лекарство: placebo
placebo delivered via Concept 1 inhaler

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85)
Временное ограничение: after 12 weeks (Day 85)
Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)
after 12 weeks (Day 85)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85)
Временное ограничение: aftert 12 weeks (Day 85)
The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.
aftert 12 weeks (Day 85)
Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment.
Временное ограничение: Day 15, Day 29 and Day 57
Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.
Day 15, Day 29 and Day 57
Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points
Временное ограничение: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Временное ограничение: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Временное ограничение: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&12 Weeks (Day 84)
Временное ограничение: Day 1, 2 Weeks, 12 Weeks
Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.
Day 1, 2 Weeks, 12 Weeks
Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84)
Временное ограничение: Day 1, 2 weeks (Day 14), 12 weeks (Day 84)
Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.
Day 1, 2 weeks (Day 14), 12 weeks (Day 84)
Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment
Временное ограничение: after 4 weeks (Day 29) and after 8 weeks (Day 57)
The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
after 4 weeks (Day 29) and after 8 weeks (Day 57)
Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period.
Временное ограничение: baseline, 4weeks, 8 weeks and 12 weeks
PEFR is measured with portable spirometer by participants every morning and evening at home.
baseline, 4weeks, 8 weeks and 12 weeks
The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment
Временное ограничение: 12 weeks
Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.
12 weeks
Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment
Временное ограничение: 4 Weeks, 12 Weeks
The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and > 1.5 as marked clinically important differences for any individual domain or for the overall summary score.
4 Weeks, 12 Weeks
Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
Duration of treatment until first asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations. Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates. The estimates are obtained from the model and so we cannot specify a formula.
12 weeks
Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
Duration of asthma exacerbations by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
The percentage of patients with at least one asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
Time to permanent study discontinuation due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
The percentage of patients who permanently discontinued study due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period
Временное ограничение: 12 weeks
Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
12 weeks
Plasma Indacaterol Concentrations at Day 1 and Day 14
Временное ограничение: Day 1 and Day 14
Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup
Day 1 and Day 14

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Novartis Pharmaceuticals

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования

1 августа 2012 г.

Первичное завершение (Действительный)

1 июля 2013 г.

Завершение исследования (Действительный)

1 июля 2013 г.

Даты регистрации исследования

Первый отправленный

23 апреля 2012 г.

Впервые представлено, что соответствует критериям контроля качества

29 мая 2012 г.

Первый опубликованный (Оценивать)

1 июня 2012 г.

Обновления учебных записей

Последнее опубликованное обновление (Оценивать)

27 января 2015 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

15 января 2015 г.

Последняя проверка

1 января 2015 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • CQMF149E2203
  • 2012-000520-18 (Номер EudraCT)

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Искать похожие исследования

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

CROs by country

CROs in Kenya

Заболевания

Редкие заболевания

Медикаментозные вмешательства

Пищевые добавки

Спонсор / Соавторы

Места

Подписаться